Monte Rosa Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Monte Rosa Therapeutics, Inc. (GLUE) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.34M, a 178.41% decline year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.92M, a 72925.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.38M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$941.00K, a 137.22% decline year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$604.00K, a 138.04% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.59M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.08M, a 150.63% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.13M, a 202.13% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.58M 10-Q · filed 2026-08-06 | $205.00K derived: sum of 3 quarters · filed 2026-08-06 | -$736.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.92M 10-Q · filed 2026-05-07 | $1.54M derived: sum of 2 quarters · filed 2026-05-07 | $604.00K derived: sum of 3 quarters · filed 2026-05-07 | $2.31M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$2.32M derived: sum of 2 quarters · filed 2026-03-17 | -$608.00K derived: sum of 3 quarters · filed 2026-08-06 | -$604.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$941.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $768.00K derived: sum of 2 quarters · filed 2026-08-06 | $772.00K 10-Q · filed 2025-11-06 | -$2.58M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.71M 10-Q · filed 2026-08-06 | -$1.64M derived: sum of 3 quarters · filed 2026-08-06 | $889.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-07 | -$3.35M derived: sum of 2 quarters · filed 2026-05-07 | -$820.00K derived: sum of 3 quarters · filed 2026-05-07 | -$695.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$824.00K derived: sum of 2 quarters · filed 2026-03-17 | -$699.00K derived: sum of 3 quarters · filed 2026-03-17 | $1.59M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.65M derived: sum of 2 quarters · filed 2025-11-06 | $4.94M 10-Q · filed 2025-11-06 | $4.17M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.41M 10-Q · filed 2025-08-07 | $1.65M derived: sum of 3 quarters · filed 2025-08-07 | $1.88M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $2.29M 10-Q · filed 2025-05-08 | $1.52M derived: sum of 2 quarters · filed 2025-05-08 | $1.76M derived: sum of 3 quarters · filed 2025-05-08 | $2.53M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$765.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$530.00K derived: sum of 2 quarters · filed 2025-03-20 | $243.00K derived: sum of 3 quarters · filed 2025-03-20 | -$1.08M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.01M derived: sum of 2 quarters · filed 2024-11-07 | -$312.00K 10-Q · filed 2024-11-07 | -$307.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $773.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$547.00K 10-Q · filed 2024-08-08 | -$542.00K derived: sum of 3 quarters · filed 2024-08-08 | $892.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$1.32M 10-Q · filed 2024-05-09 | $1.32M 10-Q · filed 2023-05-11 | -$1.31M derived: sum of 2 quarters · filed 2024-05-09 | $119.00K derived: sum of 3 quarters · filed 2024-05-09 | $199.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.44M derived: sum of 2 quarters · filed 2024-03-14 | $1.52M derived: sum of 3 quarters · filed 2024-03-14 | $2.13M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.51M derived: sum of 2 quarters · filed 2023-11-09 | $2.12M 10-Q · filed 2023-11-09 | $1.23M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $688.00K 10-Q · filed 2023-08-10 | -$201.00K derived: sum of 3 quarters · filed 2023-08-10 | $2.06M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $608.00K 10-Q · filed 2023-05-11 | -$281.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.98M derived: sum of 3 quarters · filed 2023-05-11 | -$69.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.37M derived: sum of 2 quarters · filed 2023-03-16 | -$677.00K derived: sum of 3 quarters · filed 2023-03-16 | $704.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $212.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.59M 10-Q · filed 2022-11-10 | $2.29M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$663.00K 10-Q · filed 2022-08-11 | $38.00K derived: sum of 3 quarters · filed 2022-08-11 | $192.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.38M 10-Q · filed 2022-05-11 | $2.08M derived: sum of 2 quarters · filed 2022-05-11 | $2.24M derived: sum of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $855.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.38M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $676.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $522.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |